Institute of Biotechnology, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
Graduate University of Sciences and Technology, Vietnam Academy of Science and Technology, Hanoi, Vietnam.
J Immunol Res. 2021 Jun 2;2021:5575260. doi: 10.1155/2021/5575260. eCollection 2021.
CD47 is a cell surface glycoprotein molecule, belonging to the immunoglobulin superfamily, binding to various proteins including integrins, thrombospondin-1, and signal regulatory protein (SIRP). CD47 is an important tumor antigen for the development and progression of various cancers. This study designed the chimeric antigen receptor T-cell (CAR-T) to bind to the CD47 to inhibit the expression of CD47. We used the complementarity-determining regions (CDRs) of the B6H12 mouse antibody grafted onto the IgG1 framework to create the humanized single-chain variable fragment (scFv) with linker (G4S)x3. scFv was used to design the chimeric antigen receptor with the structure CD8signal-CD47scFv-CD8a hinge-CD4TM-CD28-41BB-CD3, which was then transformed into T lymphocytes by the lentivirus to create third generation of CAR-T. Results revealed that the new CAR-T cells efficiently killed A549 cancer cells. CAR-T inhibited the expression of genes involved in metastasis and invasion of cells A549 including beta actin, calreticulin, and cyclooxygenase 2 at mRNA levels.
CD47 是一种细胞表面糖蛋白分子,属于免疫球蛋白超家族,与包括整合素、血小板反应蛋白-1 和信号调节蛋白 (SIRP) 在内的各种蛋白质结合。CD47 是各种癌症发生和发展的重要肿瘤抗原。本研究设计嵌合抗原受体 T 细胞 (CAR-T) 与 CD47 结合,抑制 CD47 的表达。我们使用 B6H12 小鼠抗体的互补决定区 (CDRs) 移植到 IgG1 框架上,构建了带有连接子 (G4S)x3 的人源化单链可变片段 (scFv)。scFv 用于设计具有结构 CD8signal-CD47scFv-CD8a 铰链-CD4TM-CD28-41BB-CD3 的嵌合抗原受体,然后通过慢病毒将其转化为 T 淋巴细胞,构建第三代 CAR-T。结果表明,新型 CAR-T 细胞能够有效杀伤 A549 癌细胞。CAR-T 在 mRNA 水平上抑制了细胞 A549 中参与转移和侵袭的基因的表达,包括β肌动蛋白、钙网蛋白和环氧化酶 2。